Biogen (BIIB) receives European Commission approval for high dose regimen of Spinraza (Nusinersen) for spinal muscular atrophy

Biogen's approval of the high dose regimen of Spinraza by the European Commission could signal enhanced treatment options for spinal muscular atrophy, positively impacting the drug's revenue potential.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Novo Nordisk (NVO) CEO says Trump administration's straightforward approach has made deal-making easier, via JP Morgan conference

Apple (AAPL) and Google (GOOGL) confirm they have entered into a multi-year deal where next generation of Apple Foundation models will be based on Google's Gemini models

Biogen (BIIB) receives European Commission approval for high dose regimen of Spinraza (Nusinersen) for spinal muscular atrophy

Republican Senator Murkowski says if DoJ believes an investigation into Fed Chair Powell is warranted based on project cost overruns then congress needs to investigate the DoJ

Newsquawk Daily Economic Releases - 13th January 2026

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This development might strengthen Biogen's position in the biotechnology sector and could elicit bullish sentiment in both the stock and related biotech equities. Watch for potential peer movement as investors assess the implications for competition in the market.

Related headlines

The whole workspace, free to try.

Try it free